Page 4«..3456..1020..»

BioSenic provides First Quarter 2024 Business Update

Posted: May 27, 2024 at 2:47 am

PRESS RELEASE – REGULATED INFORMATION

Read the original post:
BioSenic provides First Quarter 2024 Business Update

Posted in Global News Feed | Comments Off on BioSenic provides First Quarter 2024 Business Update

Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.

Posted: May 27, 2024 at 2:47 am

Hugues Lecat appointed Chairman of the Board of Directors of Guerbet

Read more from the original source:
Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.

Posted in Global News Feed | Comments Off on Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.

Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index

Posted: May 27, 2024 at 2:47 am

Has the potential to Enhance the visibility of Scilex’s Non-Opioid Pain Management Therapeutics In Global Financial Markets Has the potential to Enhance the visibility of Scilex’s Non-Opioid Pain Management Therapeutics In Global Financial Markets

See the original post:
Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index

Posted in Global News Feed | Comments Off on Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index

Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome

Posted: May 27, 2024 at 2:47 am

WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a potential therapeutic option in patients with Macrophage Activation Syndrome (MAS). Emapalumab is a fully human, anti-IFN? monoclonal antibody that binds free and receptor-bound IFN?, neutralizing its biological activity. Emapalumab is currently in Phase lll development for MAS.

View original post here:
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome

Posted in Global News Feed | Comments Off on Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome

Iovance Biotherapeutics to Present at Upcoming Conferences and Events

Posted: May 27, 2024 at 2:47 am

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events:

Original post:
Iovance Biotherapeutics to Present at Upcoming Conferences and Events

Posted in Global News Feed | Comments Off on Iovance Biotherapeutics to Present at Upcoming Conferences and Events

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

Posted: May 27, 2024 at 2:47 am

ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company’s securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”).

See more here:
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

Posted in Global News Feed | Comments Off on OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting

Posted: May 27, 2024 at 2:47 am

WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 – June 4, 2024.

View original post here:
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting

Posted in Global News Feed | Comments Off on Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting

Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Posted: May 27, 2024 at 2:47 am

All monetary figures listed in Canadian Dollars.

See the original post:
Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Posted in Global News Feed | Comments Off on Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Posted: May 27, 2024 at 2:47 am

FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended March 31, 2024 (“Q1 2024 Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”), does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively.

Read the original post:
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Posted in Global News Feed | Comments Off on Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically…

Posted: May 27, 2024 at 2:47 am

Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure14,15.

More:
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically...

Posted in Global News Feed | Comments Off on Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically…

Page 4«..3456..1020..»